Skip to main navigation Skip to search Skip to main content

A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Myasthenia Gravis who have Generealized Muscle Weakness

Project: Research

Project Details

StatusFinished
Effective start/end date09/7/17 → 12/31/22

Funding

  • argenx BVBA: $5,000.00